抗体作为宿主适应性免疫系统的最重要组成部分之一，在抵御感染性疾病、免疫监测和自身免疫性疾病中发挥重要作用。由于重组抗体技术的发展，抗体治疗成为提供重大健康效益的最大且迅速扩大的药物，特别是对于癌症患者的治疗。许多基于抗体的治疗策略已经开发出来，包括单克隆抗体、抗体药物偶联物、双特异性和三特异性抗体以及前体抗体，这些策略在临床和临床前试验中的结果令人鼓舞。然而，对于不同机制的患者，治疗反应率和副作用仍然存在差异。因此，本文总结了抗体为基础的癌症免疫治疗策略的当前和未来观点，以设计下一代药物。© 2023 作者，由德格鲁伊特出版，柏林/波士顿发表。

Antibodies, as one of the most important components of host adaptive immune system, play an important role in defense of infectious disease, immune surveillance, and autoimmune disease. Due to the development of recombinant antibody technology, antibody therapeutics become the largest and rapidly expanding drug to provide major health benefits to patients, especially for the treatment of cancer patients. Many antibody-based therapeutic strategies have been developed including monoclonal antibodies, antibody-drug conjugates, bispecific and trispecific antibodies and pro-antibodies with promising results from both clinical and pre-clinical trials. However, the response rate and side-effect still vary between patients with undefined mechanisms. Here, we summarized the current and future perspectives of antibody-based cancer immunotherapeutic strategies for designing next-generation drugs.© 2023 the author(s), published by De Gruyter, Berlin/Boston.